Federal officials could give the FDA authority to develop e-cigarette regulations. But developing regulations that maximize their benefits and minimize their risks is harder than it looks.
Academic rigour, journalistic flair
Articles on Food and Drug Administration (FDA)
Displaying 141 - 160 of 161 articles
Thalidomide’s manufacturer, Chemie Grünenthal, marketed the drug as safe for pregnant women despite reports it was causing malformations in newborns. Why such blatant denial?
Thalidomide was marketed as a safe, sleep-inducing drug, but when taken during pregnancy it could cause severe birth defects.
Documents reveal thalidomide’s manufacturer was warned about possible harms as early as 1956.
Before the last round of negotiations, only a handful of issues remained in the way of concluding the TPP. A potential deal-breaker for Australia was intellectual property protections for biologics.
As part of an intiative to re-examine misrepresented or abandoned studies, we re-analysed an antidepressant trial. Here’s what we found.
The Victorian government is calling on other state governments to join it in banning powdered alcohol, which was recently approved for marketing and sale in the US.
Medical tourism is the practice of seeking medical care across international borders. Countries with established medical sectors like the US, Europe, India and Thailand have been traditional destinations…
In the last six months Colorado, Louisiana, Missouri, Michigan and, most recently, Arizona have passed “right to try” laws that allow terminally ill patients to access treatments that have only passed…
On November 4, the state of Arizona will decide whether to join Colorado, Missouri, Louisiana and Michigan in passing so-called right to try laws. If passed, the “Arizona Terminal Patients’ Right To Try…
This article contains spoilers. In the award-winning movie The Dallas Buyers Club, Matthew McConaughey plays the role of Ron Woodroof, a real-life Texas cowboy who was diagnosed with HIV/AIDS in 1985…
Developing new drugs is hard and expensive. The lengthy process from initial discovery to the market is some times compared to the difficulty of putting a person on the moon. Despite accusations that the…
Between 2005 and 2011, nearly half of all new drug formulations in the US were approved without companies having to demonstrate a tangible benefit, such as relieving disease symptoms, extending life, or…
The market for personal genome services is facing a reality check. While the most prominent and innovative company 23andMe has flourished so far, in the past few years many of its competitors have gone…
Genetic testing is a powerful tool. Two years ago, with the help of my colleagues, it was this tool that helped us identify a new disease. The disease, called Ogden Syndrome, caused the death of a four-month…
The increased supply and marketing of processed food high in fat, sugar and salt are recognised as the major drivers of obesity and diet-related diseases globally. As part of efforts to improve the healthiness…
In 2001 I met David Graham, an official from the US Food and Drug Administration, in a car park in Washington. I wanted him to shed light on why the diabetes drug troglitazone, or Rezulin, had been available…
The US Food and Drug Administration (FDA) is investigating a series of deaths reportedly linked to the consumption of energy drinks and shots. The investigation comes amid a growing number of reports of…
New medicines must be approved as safe, efficacious and of good quality before they can be prescribed. But authors of two recent articles in the British Medical Journal argue that governments should introduce…
The US Food and Drug Administration (FDA) recently revised the safety labels for statins, widely used anti-cholesterol drugs. They mandated label warnings saying statins may increase the risk of type 2…
Top contributors
-
Distinguished Professor of Pharmacy Practice, University of Connecticut
-
Professor of Law, Villanova School of Law
-
Associate Professor of Public Policy, University of Maryland, Baltimore County
-
Associate Professor of Pharmacy and Therapeutics, University of Pittsburgh
-
Joel Lexchin is a Friend of The Conversation.
Professor Emeritus of Health Policy and Management, York University, Canada
-
Associate Professor of Molecular Medicine, UMass Chan Medical School
-
Professor and Dean, School of Public Health, Georgia State University
-
Instructor of Human Immunology, Emory University
-
Associate Professor of Pediatrics, University of Virginia
-
Clinical Associate Professor of Pharmacy Practice, Binghamton University, State University of New York
-
Associate Professor of Operations and Decision Technologies, Kelley School of Business, Indiana University
-
Professor of Law, George Washington University
-
Doctorate in Health Sciences candidate, George Washington University
-
Professor and Director of Quantitative Biosciences Institute & Senior Investigator at the Gladstone Institutes, University of California, San Francisco
-
Associate Professor of Legal Studies and Political Science, UMass Amherst
